Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;166(6):1329-1333.
doi: 10.1016/j.chest.2024.05.041. Epub 2024 Jul 5.

Eosinopenia as Predictor of Disease Severity in Patients With Community-Acquired Pneumonia: An Observational Study

Barbara Christine Weckler  1 , Hendrik Pott  1 , Alan Race  2 , Nattika Jugkaeo  3 , Kapil Karki  3 , Stephan Ringshandl  3 , Christian Seidemann  4 , Ines Schöndorf  5 , Harald Renz  6 , Sebastian Fähndrich  7 , Anna Lena Jung  8 , Wilhelm Bertrams  9 , Adeline Makoudjou  10 , Daniela Zöller  11 , Susetta Finotto  12 , Stefanie Schild  13 , Susanne A Seuchter  13 , Gernot Rohde  14 , Frederik Trinkmann  15 , Timm Greulich  16 , Claus Franz Vogelmeier  17 , Bernd Schmeck  18
Affiliations

Eosinopenia as Predictor of Disease Severity in Patients With Community-Acquired Pneumonia: An Observational Study

Barbara Christine Weckler et al. Chest. 2024 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: B. C. W. reports one unpaid participation in an Advisory Board with AstraZeneca. A. L. J. reports research grants from the Behring Röntgen Foundation. G. R. reports personal fees from Astra Zeneca, Atriva, Boehringer Ingelheim, GSK, Insmed, MSD, Sanofi, Novartis, and Pfizer for consultancy during advisory board meetings and personal fees from Astra Zeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Sanofi, Solvay, Takeda, Novartis, Pfizer, and Vertex for lectures including service on speakers’ bureaus. F. T. reports consulting fees from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Fisher & Paykel, GlaxoSmithKline, Janssen-Cilag, Novartis, Omron, OM-Pharma, Roche, Sanofi-Aventis, and support for attending meetings or travel from AstraZeneca, Actelion, Bayer, Berlin Chemie, Boehringer Ingelheim, Chiesi, Mundipharma, Novartis, Pfizer, TEVA. T. G. reports Grant from Grifols to institution for AATD laboratory, consulting fees from AstraZeneca, Berlin-Chemie, Boehringer-Ingelheim, Chiesi, CSL-Behring, Grifols, GSK, Mundipharma, Novartis, Takeda, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Berlin-Chemie, Boehringer-Ingelheim, Chiesi, CSL-Behring, Grifols, GSK, Mundipharma, Takeda, support for attending meetings or travel from AstraZeneca, Berlin-Chemie, Chiesi, CSL-Behring, Grifols, GSK, Novartis, participation on a Data Safety Monitoring Board or Advisory Board with AstraZeneca, Berlin-Chemie, Boehringer-Ingelheim, Chiesi, CSL-Behring, Grifols, GSK, Mundipharma, Novartis, Takeda, leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as scientific Advisor for Alpha-1-Deutschland. C. F. V. reports grants or contracts from German Ministery of Education and Science (BMBF), AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Grifols, Novartis, consulting fees from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Insmed, Menarini, Novartis, Nuvaira, Sanofi, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Insmed, Menarini, Novartis, Roche, Sanofi. Bernd Schmeck reports Grants or contracts from CSL-Behring. None declared (H. P., A. R., N. J., K. K., S. R., C. S., I. S., H. R., S. Fähndrich., W. B., A. M., D. Z., S. Finotto., S. S., S. A. S., B. S.).

Figures

Figure 1
Figure 1
In-hospital mortality in the eosinopenia vs non-eosinopenia group on days 1, 5, 10, 15, and 30 after hospitalization.
See this image and copyright information in PMC

References

    1. World Health Organization The Top 10 Causes of Death, Updated December 9, 2020 World Health Organization website. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
    1. Ewig S., Birkner N., Strauss R., et al. New perspectives on community-acquired pneumonia in 388 406 patients: results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009;64:1062–1069. - PMC - PubMed
    1. Mao Y., Qian Y., Sun X., et al. Eosinopenia predicting long-term mortality in hospitalized acute exacerbation of COPD patients with community-acquired pneumonia: a retrospective analysis. Int J Chron Obstruct Pulmon Dis. 2021;16:3551–3559. - PMC - PubMed
    1. Cazzaniga M., Fumagalli L.A.M., D’angelo L., et al. Eosinopenia is a reliable marker of severe disease and unfavourable outcome in patients with COVID-19 pneumonia. Int J Clin Pract. 2021;75 - PMC - PubMed
    1. Federal Institute for Drugs and Medical Devices ICD-10-GM: international statistical classification of diseases, German modification. Federal Institute for Drugs and Medical Devices website. https://www.bfarm.de/EN/Code-systems/Classifications/ICD/ICD-10-GM/_node...

LinkOut - more resources